中西医结合治疗慢性乙型肝炎病毒携带者65例临床观察

Clinical effect of integrated traditional Chinese and Western medicine therapy in treatment of chronic hepatitis B virus carriers: an analysis of 65 cases

目的:观察温肾解毒协定方联合干扰素治疗肾虚毒伏型HBeAg阳性慢性乙型肝炎病毒携带者的临床疗效。方法:将125例慢性乙型肝炎病毒携带者分为治疗组与对照组,治疗组65例采用温肾解毒协定方合干扰素治疗,对照组60例单用干扰素治疗,疗程均为48周。观察两组中医证候疗效及治疗后外周血白细胞计数、HBV DNA、HBeAg/HBeAb、肝功能的变化情况。结果:中医证候疗效总有效率治疗组为87.7%,对照组为63.3%,组间比较,差异有统计学意义(P<0.05);治疗后治疗组HBV DNA阴转率、HBe Ab/HBeAg血清转换率及肝功能ALT、TBiL检测结果与对照组比较,差异均有统计学意义(P<0.05)。结论:温肾解毒协定方联合干扰素治疗肾虚毒伏型HBeAg阳性慢性乙型肝炎病毒携带者的疗效明显优于单用干扰素治疗。

Objective： To investigate the clinical effect of Wenshen Jiedu cipher prescriptioncombined with interferon in the treatment of HBe Ag- positive chronic hepatitis B virus carriers with kidney deficiency and toxin retention. Methods： A total of 125 chronic hepatitis B virus carriers were divided into treatment group and control group. The 65 patients in the treatment group were given Wenshen Jiedu prescription combined with interferon,and the 60 patients in the control group were giveninterferon alone. The course of the treatment was 48 weeks for both groups. The clinical outcome of traditional Chinese medicine（ TCM） syndrome and changes in peripheral leukocyte count,HBV DNA,HBeAg / HBeAb,and liver function after treatment were observed in both groups. Results： There was a significant difference in the overall TCM syndrome response rate between the treatment group and the control group（ 87. 7% vs 63. 3%,P〈0. 05）. There were also significant differences in HBV DNA clearance rate,HBe Ab/HBeAg seroconversion rate,and the liver function parameters alanine aminotransferase and total bilirubin between the two group（ P〈0. 05）. Conclusion： In the treatment of HBeAg- positive chronic hepatitis B virus carriers with kidney deficiency and toxin retention,Wenshen Jiedu prescription combined with interferonhave a significantly better clinical effect than interferon alone.